Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In recognition of the new links with the Nuffield Department of Clinical Neurosciences and the Department of Experimental Psychology, the Oxford Clinical Trials Unit for Mental Illness (OCTUMI) has a new name: the Oxford Cognitive Health and Neuroscience Clinical Trials Unit (OCHNCTU, pronounced oc-n-tü) and a new logo.

The OCHNCTU portfolio will, in future, include trials for neurological conditions and cognitive neuroscience. The CTU offers advice and support in all aspects of the planning, conducting and reporting of clinical trials. Key areas of expertise include statistics, trial management, quality assurance, database provision and data management. Where resources permit, specific services (such as a randomisation program or trial monitoring) can be provided.

 

OCHNCTU projects include both non-commercial efficacy trials designed to reduce the uncertainties associated with current treatments and early phase trials evaluating potential new treatments. The CTU is working closely with the Oxford NHS Trusts to increase research productivity and recruitment into trials and has links with TVCLRN, DeNDRoN, the MHRN and other Oxford University Clinical Trials Units. OCHNCTU is also closely affiliated to the Oxford Cognitive Health Clinical Research Facility which supports the translation of neuroscience discoveries into effective therapies. 

For more information, contact Dr Jennifer Rendell on 01865 226465, email ochnctu@psych.ox.ac.uk

Similar stories

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from researchers at the Department of Paediatrics and the Nuffield Department of Clinical Neurosciences has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.

Funding awarded for autoimmune disease research

Dr Kate Attfield awarded project funding by Connect Immune Research and The Lorna and Yuti Chernajovsky Biomedical Research Foundation.

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.

Little understood brain region linked to how we perceive pain

A new DPAG-led review paper, published in the journal Brain, has shown that a poorly understood region of the brain called the claustrum may play an important role in how we experience pain.

New funding awarded to study persistent pain in inflammatory arthritis

The £3.9M Wellcome Collaborative Award will be used to identify the drivers of pain in people living with rheumatoid arthritis.

First-in-human implant of a “closed-loop” bioelectronic research system for investigating treatments for brain disorders

Researchers at Oxford University have implanted a novel closed-loop research platform for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in Parkinson’s-like Multiple Systems Atrophy (MSA).